JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB181142

Anti-PCSK9 抗体 [EPR7627(2)]

Anti-PCSK9 antibody [EPR7627(2)]

Be the first to review this product! Submit a review

|

(29 Publications)

Anti-PCSK9 antibody [EPR7627(2)] (ab181142) is a rabbit monoclonal antibody detecting PCSK9 in Western Blot, IP. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency
- Over 10 publications

別名を表示する

NARC1, PSEC0052, PCSK9, Proprotein convertase subtilisin/kexin type 9, Neural apoptosis-regulated convertase 1, Proprotein convertase 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9

6 Images
Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • IP

Supplier Data

Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

Western blot analysis of PCSK9 in HepG2 cell lysate immunoprecipitated using unpurified ab181142 at a dilution of 1/50.

Secondary : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution.

All lanes:

Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (ab181142)

Predicted band size: 74 kDa

Observed band size: 62 kDa

false

Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • IP

Lab

Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

ab181142 (purified) at 1/50 immunoprecipitating PCSK9 in HepG2 whole cell lysate.

Lane 1 (input) : HepG2 whole cell lysate (10μg)

Lane 2 (+) : ab181142 + HepG2 whole cell lysate.

Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab181142 in HepG2 whole cell lysate.

For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Immunoprecipitation - Anti-PCSK9 antibody [EPR7627(2)] (ab181142)

Predicted band size: 74 kDa

Observed band size: 62 kDa,78 kDa

false

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • WB

Lab

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (ab181142) at 1/20000 dilution

Lane 1:

A431 whole cell lysate at 10 µg

Lane 2:

HepG2 whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Predicted band size: 74 kDa

Observed band size: 62 kDa,78 kDa

false

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • WB

Supplier Data

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

All lanes:

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (ab181142) at 1/10000 dilution

Lane 1:

A431 (Human epidermoid carcinoma cell line) cell lysate at 20 µg

Lane 2:

HepG2 (Human liver hepatocellular carcinoma cell line) cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 74 kDa

Observed band size: 62 kDa,78 kDa

false

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • WB

Lab

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

Blocking and dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (ab181142) at 1/5000 dilution

All lanes:

BxPC-3 whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/5000 dilution

Predicted band size: 23 kDa,39 kDa,48 kDa,74 kDa

Observed band size: 26 kDa,39 kDa,62 kDa,78 kDa

false

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)
  • WB

Supplier Data

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (AB181142)

All lanes:

Western blot - Anti-PCSK9 antibody [EPR7627(2)] (ab181142) at 1/2000 dilution

All lanes:

Human fetal liver lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 74 kDa

Observed band size: 62 kDa

false

関連する標識済み抗体及び組成の異なる製品 (2)

  • Carrier free

    Anti-PCSK9 antibody [EPR7627(2)] - BSA and Azide free

  • HRP

    HRP Anti-PCSK9 antibody [EPR7627(2)]

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR7627(2)

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

WB, IP

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

代替製品

Primary Antibodies

AB28770

Anti-PCSK9 antibody

  • 4
  • 2
Primary Antibodies

AB246322

Anti-PCSK9 antibody [EPR17827-117] - BSA and Azide free

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-PCSK9 antibody [EPR17827-117] - BSA and Azide free (AB246322)

  • 0
  • 0
Primary Antibodies

AB185194

Anti-PCSK9 antibody [EPR17827-117]

RabMAb|Recombinant|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PCSK9 antibody [EPR17827-117] (AB185194)

  • 0
  • 0

組合せ製品

Assay Kits

AB209884

Human PCSK9 ELISA Kit

Recombinant|SimpleStep

ELISA - Human PCSK9 ELISA Kit (AB209884)

  • 0
  • 0
Primary Antibodies

AB52818

Anti-LDL Receptor antibody [EP1553Y]

20ul selling size|RabMAb|KO Validated|Recombinant

Western blot - Anti-LDL Receptor antibody [EP1553Y] (AB52818)

  • 4
  • 16
Primary Antibodies

AB30682

Anti-SREBP2 antibody

Immunocytochemistry/ Immunofluorescence - Anti-SREBP2 antibody (AB30682)

  • 4
  • 12
Primary Antibodies

AB181602

Anti-GAPDH antibody [EPR16891] - Loading Control

KD Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GAPDH antibody [EPR16891] - Loading Control (AB181602)

  • 5
  • 23
Primary Antibodies

AB32537

Anti-ERK1 antibody [Y72]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size

Flow Cytometry (Intracellular) - Anti-ERK1 antibody [Y72] (AB32537)

  • 5
  • 4
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30 - 1/50", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>" } } }
style
left-column

製品の詳細

What is this antibody validated in?
Anti-PCSK9 antibody [EPR7627(2)] (ab181142) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP) in Human samples.

What is the molecular weight of PCSK9?
Anti-PCSK9 [EPR7627(2)] (ab181142) specifically detects a band for PCSK9 (UniProt: Q8NBP7) at a molecular weight of 74kDa.

Trusted by the scientific community
Anti-PCSK9 [EPR7627(2)] (ab181142) was first used in a scientific publication in 2013 and has been cited over 10 times in peer-reviewed journals.

Other related products
We have a range of other formats of antibody clone [EPR7627(2)] also available for your convenience: ab181142, Carrier free - ab238995, HRP - ab323661

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Conditional Ambient
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein responsible for the regulation of cholesterol levels by binding to low-density lipoprotein receptors (LDLR) on hepatocytes. This interaction marks the LDLRs for degradation reducing the liver's ability to clear LDL cholesterol from the blood. PCSK9 has a molecular weight of approximately 74 kDa. The protein is mainly expressed in the liver but is also found in the intestine and kidneys. PCSK9 is referred to as NARC-1 standing for neural apoptosis-regulated convertase 1 highlighting its role in the liver's cholesterol management system.
Biological function summary

PCSK9 influences cholesterol homeostasis by its important role in degrading LDL receptors. It functions independently rather than as part of larger protein complexes. PCSK9 gains particular interest in therapeutic contexts where its inhibition can lead to increased LDLR levels and enhanced clearance of LDL cholesterol. Biotinylated PCSK9 and mouse PCSK9 variants provide significant tools for experimental study. Kits such as the PCSK9 ELISA kit enable detailed measurement of PCSK9 levels in blood samples providing insights into cholesterol metabolism dynamics.

Pathways

PCSK9 operates within the lipid metabolism pathway and the cholesterol biosynthesis pathway. The protein's activity affects the fate of LDL cholesterol within these pathways. It interacts with proteins such as apolipoprotein B (ApoB) which plays a central role in the structural component of LDL particles. The modulation of these pathways by PCSK9 highlights the significance of its function in maintaining cardiovascular health and managing cholesterol levels.

PCSK9 is closely linked to hypercholesterolemia and coronary artery disease. Mutations in PCSK9 can lead to autosomal dominant hypercholesterolemia due to its effect on LDL receptor degradation. Other proteins such as ApoB and LDLR are involved in these conditions tightly interacting with PCSK9's regulatory function. A better understanding of PCSK9's role offers potential therapeutic targets for cardiovascular disease interventions especially through the development of PCSK9 antibodies and PCSK9 assays that adjust cholesterol levels.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members : low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed : 18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed : 17461796, PubMed : 18197702, PubMed : 18799458, PubMed : 22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed : 18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
See full target information PCSK9
style
left-column

文献 (29)

Recent publications for all applications. Explore the full list and refine your search

Food & function 16:7823-7834 PubMed40938307

2025

Effects of 'Mapo' tangelo ( × ) extracts, essential oil, and isolated compounds on LDL receptor and PCSK9 expression in the human hepatocarcinoma cell line Huh7.

Applications

Unspecified application

Species

Unspecified reactive species

Irene Ferrarese,Maria Giovanna Lupo,Ilaria Rossi,Giorgia Marodin,Haixia Chen,Stefania Sut,Nicola Ferri,Stefano Dall'Acqua

Cardiovascular research 121:1373-1384 PubMed40653676

2025

Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation.

Applications

Unspecified application

Species

Unspecified reactive species

Srividya Velagapudi,Melroy X Miranda,Priyanka Adla,Simon Kraler,Shafeeq A Mohammed,Shekhar Baki,Jerome Robert,Lucia Rohrer,Hwan Lee,Hyun-Duk Jang,Slayman Obeid,Anne Tailleux,Bart Staels,Naresh Babu V Sepuri,Francesco Paneni,Ravi Kumar Gutti,Arnold von Eckardstein,Hyo-Soo Kim,Alexander Akhmedov,Giovanni G Camici,Thomas F Lüscher

Cancers 17: PubMed40563628

2025

Inhibition of PCSK9 Attenuates Liver Endothelial Cell Activation Induced by Colorectal Cancer Stem Cells During Liver Metastasis.

Applications

Unspecified application

Species

Unspecified reactive species

Ander Martin,Daniela Gerovska,Marcos J Arauzo-Bravo,Maitane Duarte García-Escudero,Helena García García,Iratxe Bañares,Naroa Fontal,Geraldine Siegfried,Serge Evrad,Simon Pernot,Abdel-Majid Khatib,Iker Badiola

Scientific reports 15:15696 PubMed40325086

2025

Kratom leaf extracts exert hypolipidaemic effects via the modulation of PCSK9 and LDLR pathways in HepG2 cells.

Applications

Unspecified application

Species

Unspecified reactive species

Nantiya Nawaka,Monthon Lertcanawanichakul,Sureerut Porntadavity,Burabha Pussadhamma,Nutjaree Jeenduang

Biology direct 20:46 PubMed40189560

2025

CAP1: a novel extracellular vesicle marker linked to endothelial senescence in atherosclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Ignacio Hernandez,Laura Botana,Javier Diez-Mata,Laura Tesoro,Beatriz Jimenez-Guirado,Claudia Gonzalez-Cucharero,Nunzio Alcharani,Jose Luis Zamorano,Marta Saura,Carlos Zaragoza

Frontiers in genetics 15:1469094 PubMed39628814

2024

MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Xuemei Chen,Ying Liu,Qiujing Zhou,Chenxi Zhang,Wei Wang,Menglong Xu,Yaqiang Zhao,Wenfeng Zhao,Dian Gu,Shuhua Tan

ACS omega 9:24308-24320 PubMed38882153

2024

Quantitative Proteomics Reveal the Role of Matrine in Regulating Lipid Metabolism.

Applications

Unspecified application

Species

Unspecified reactive species

Huixu Feng,Guobin Liu,Luhan Li,Xuelian Ren,Yue Jiang,Wanting Hou,Ruilong Liu,Kun Liu,Hong Liu,He Huang

European journal of medicinal chemistry 265:116063 PubMed38160616

2024

Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability.

Applications

Unspecified application

Species

Unspecified reactive species

Lisa Giannessi,Maria Giovanna Lupo,Ilaria Rossi,Maria Grazia Martina,Antonietta Vilella,Martina Bodria,Daniela Giuliani,Francesca Zimetti,Ilaria Zanotti,Francesco Potì,Franco Bernini,Nicola Ferri,Marco Radi

Journal of experimental & clinical cancer research : CR 41:303 PubMed36242053

2022

PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages.

Applications

Unspecified application

Species

Unspecified reactive species

Lu Wang,Shuangshuang Li,Huanhua Luo,Qi Lu,Shuwen Yu

Analytical biochemistry 655:114846 PubMed35973625

2022

Identification of secreted proteins by comparison of protein abundance in conditioned media and cell lysates.

Applications

Unspecified application

Species

Unspecified reactive species

Prabhodh S Abbineni,Vi T Tang,Felipe da Veiga Leprevost,Venkatesha Basrur,Jie Xiang,Alexey I Nesvizhskii,David Ginsburg
View all publications
style
left-column
style
left-column
style
right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com